| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2021-01-26 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 1,000 | 100.0% | EDGAR |
| SC 13D/A | 2021-01-26 | Eidos Therapeutics, Inc. | BridgeBio Pharma, Inc. | 0 | 0.0% | EDGAR |
| SC 13D | 2020-10-15 | Eidos Therapeutics, Inc. | BridgeBio Pharma, Inc. | 44,651,896 | 36.4% | EDGAR |
| SC 13D/A | 2020-10-07 | RA CAPITAL MANAGEMENT, L.P. | Eidos Therapeutics, Inc. | 1,798,339 | 4.7% | EDGAR |
| SC 13D/A | 2020-10-05 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 63.7% | EDGAR |
| SC 13G/A | 2020-02-11 | VIKING GLOBAL INVESTORS LP | Eidos Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2019-10-15 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 65.6% | EDGAR |
| SC 13D/A | 2019-08-08 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 66.6% | EDGAR |
| SC 13D/A | 2019-07-09 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 24,575,501 | 66.7% | EDGAR |
| SC 13D/A | 2019-05-30 | BridgeBio Pharma, Inc. | Eidos Therapeutics, Inc. | 23,693,148 | 64.3% | EDGAR |
| SC 13G/A | 2019-01-10 | VIKING GLOBAL INVESTORS LP | Eidos Therapeutics, Inc. | 1,986,201 | 5.4% | EDGAR |
| SC 13D/A | 2018-12-13 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,589,300 | 61.5% | EDGAR |
| SC 13D/A | 2018-12-11 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,548,647 | 61.4% | EDGAR |
| SC 13D/A | 2018-12-07 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 22,468,503 | 61.1% | EDGAR |
| SC 13D | 2018-08-01 | BridgeBio Pharma LLC | Eidos Therapeutics, Inc. | 19,614,655 | 54.8% | EDGAR |
| SC 13D | 2018-07-02 | RA CAPITAL MANAGEMENT, LLC | Eidos Therapeutics, Inc. | 2,162,671 | 5.9% | EDGAR |
| SC 13G | 2018-07-02 | VIKING GLOBAL INVESTORS LP | Eidos Therapeutics, Inc. | 1,986,201 | 5.4% | EDGAR |